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Development of human bodies, organs, and tissues contains numerous steps of cellular differentiation including an initial zygote,
embryonic stem (ES) cells, three germ layers, and multiple expertized lineages of cells. Induced pluripotent stem (iPS) cells
have been recently developed using defined reprogramming factors such as Nanog, Klf5, Oct3/4 (Pou5f1), Sox2, and Myc. This
outstanding innovation is largely changing life science and medicine. Methods of direct reprogramming of cells into myocytes,
neurons, chondrocytes, and osteoblasts have been further developed using modified combination of factors such as N-myc, L-myc,
Sox9, andmicroRNAs in defined cell/tissue culture conditions.Mesenchymal stem cells (MSCs) and dental pulp stem cells (DPSCs)
are also emergingmultipotent stem cells with particular microRNA expression signatures. It was shown that miRNA-720 had a role
in cellular reprogramming through targeting the pluripotency factor Nanog and induction of DNA methyltransferases (DNMTs).
This review reports histories, topics, and idea of cellular reprogramming.
1. Introduction
A term of cellular “reprogramming” has been major after
the development of induced pluripotent stem (iPS) cells [1].
For the development of iPSCs, Dr. Shinya Yamanaka was
awardedNobel prize in physiology andmedicine in 2012.The
iPS cells are embryonic stem (ES) cells-like pluripotent cells
induced using defined factors. The definition of “reprogram-
ming” in the narrow sense is like artificial dedifferentiation
(reprogram) of cells such as skin cells into ES cells-like
pluripotent stem cells. Mesenchymal stem cells (MSCs),
haematopoietic stem cells (HSCs), or neuronal stem cells
(NSCs) are also multipotent stem cells, which are inter-
mediate cells between more matured cells and pluripotent
stem cells. These intermediate stem cells have been also
investigated in reprogramming studies. More recently, a new
concept termed “direct reprogramming” has been developed.
Direct reprogramming is reprogramming of cells such as
skin cells into another type of differentiated cells in another
lineage.
2. Stem Cells, Germ Layers, and
Tissue Development
In order to understand cellular reprogramming, we need
some basic knowledge regarding tissue development. An
embryo is a multicellular diploid eukaryote in its earliest
stage of development, from the time of fertilization through
sexual reproduction until birth, hatch, or germination. ES
cells are pluripotent stem cells derived from the inner cell
mass of a blastocyst, an early-stage preimplantation embryo.
In a beginning step of embryonic development from ES cells
and the blastocyst, three germ layers are generated, ectoderm,
mesoderm, and endoderm.
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2.1. Ectoderm. Ectoderm emerges and originates from the
outer layer of germ cells. The word ectoderm comes from
the Greek ektos, meaning outside, and derma, meaning skin.
The ectoderm differentiates to form the nervous system
(spine, peripheral nerves, and brain) and tooth enamel via
ameloblasts and epidermis (the outer part of integument).
Ectoderm also forms the lining of the mouth (oral mucosa),
anus, nostrils, sweat glands, hair, and nails. In vertebrates,
the ectoderm has three parts, external ectoderm also known
as surface ectoderm, the neural crest, and neural tube. The
latter two are known as neuroectoderm as described below.
Established ectodermal markers are 𝛽-III-tubulin and Otx2.
Sasai et al. reported that ectodermal factor XFDL156 (Zfp12,
Zfp74) restricts mesodermal differentiation by inhibiting p53
that is required for mesodermal differentiation [2].
2.2. Neuroectoderm, Neurulation, and Neural Crest. Forma-
tion process of the neural tube, neural crest cells, and the epi-
dermis is called neurulation.The neural tube cells give rise to
the central nervous system (CNS). Neural crest cells give rise
to the peripheral and enteric nervous system, melanocytes,
facial cartilage, and the dentin of teeth. The epidermal cell
region gives rise to the epidermis, hair, nails, sebaceous
glands, olfactory, andmouth epithelium as well as eyes. All of
the organs that arise from the ectoderm originate from two
adjacent tissue layers, the epithelium and the mesenchyme.
Organogenesis of the ectoderm is mediated by signals such
as FGF, TGF𝛽, Wnt, and the hedgehog family. FGF-9, which
is expressed in epidermis but not in the mesenchyme, is a key
factor in the initiation of tooth germ development. FGF-10
helps to stimulate epithelial cell (ameloblast) proliferation, in
order to make larger tooth germs. Mammalian teeth develop
from oral ectoderm and neural crest ectoderm derived from
mesenchyme. There are over 170 subtypes of ectodermal
dysplasia.
2.3. Odontogenesis (Tooth Development). Tooth germ is an
aggregation of cells that eventually forms a tooth. These cells
are derived from the ectoderm of the first pharyngeal arch
and the ectomesenchyme of the neural crest [3, 4]. The tooth
germ is organized into three parts, the enamel organ, the
dental papilla, and the dental sac (or dental follicle). The cells
in the enamel organ give rise to ameloblasts, which produce
enamel. The location where the outer enamel epithelium and
inner enamel epithelium join is called the cervical loop. The
growth of cervical loop cells into the deeper tissues forms
Hertwig Epithelial Root Sheath, which determines the root
shape of the tooth. During the development, there are strong
similarities between keratinization and amelogenesis [5, 6].
Keratin is also present in epithelial cells of tooth germ. A thin
film of keratin is present on erupted tooth so calledNasmyth’s
membrane or enamel cuticle. The dental papilla contains
cells that develop into odontoblasts, which are dentin-
forming cells. Mesenchymal cells within the dental papilla
are responsible for the formation of tooth pulp. The dental
sac (or dental follicle) gives rise to cementoblasts, osteoblasts,
and fibroblasts. Cementoblasts form the cementum of a
tooth. Osteoblasts give rise to the alveolar bone surrounding
the roots of teeth. Fibroblasts are involved in developing
periodontal ligaments, which connect tooth cementum to the
alveolar bone.
Tooth have a bone-like structure and nature, whose
outside is armored by cortical calcified enamel layer. Interme-
diate ivory-like dentin layer of tooth contains dendrite-like
process of odontoblasts. Inside of tooth is called dental pulp,
which has bone-marrow-like space and contains nerves, vas-
culatures, haematopoietic cells, and matrix-producing cells,
odontoblasts. The odontoblasts are cells lining on the surface
of dentinmatrix from the pulp inside and extending dendrite-
like process through the dentinal tube. These structures
and functions of odontoblasts are similar to osteoblasts,
which are lining on the surface of bone matrix from the
bone marrow. As odontoblasts are extending dendrite-like
process, osteocytes are extending dendrites through the bone
canaliculi. Both odontoblasts and osteocytes locate close to
nerves and are the sensors as well. Such bone-marrow-like
feature of dental pulp “tooth marrow” has given us an idea
of dental pulp stem cells (DPSCs) or tooth marrow stromal
cells (TMSCs) that may contain multiple stem cells including
MSCs, HSCs, and NSCs [7–11]. Stem cells from human
exfoliated deciduous teeth (SHEDs) have been shown to be
useful as therapeutic tools [12].
2.4. Mesoderm. Mesoderm has been known as a resource of
muscle (including smooth, cardiac, skeletal, tongue, masti-
cation, and facial expressions), bone, cartilage, blood vessels,
blood cells, urogenital structures such as kidney, gonads, and
their associated ducts. A group of cells in ectoderm trans-
forms via epithelial-mesenchymal transition (EMT)migrates
between ectoderm and endoderm and then formsmesoderm.
Mesoderm has the capacity to induce the growth of other
structures, such as the neural plate, the precursor to the
nervous system. Mesoderm is formed through a process
called gastrulation. There are three components, the paraxial
mesoderm, the intermediate mesoderm and the lateral plate
mesoderm.Theparaxialmesoderm gives rise tomesenchyme
of the head and organizes into somites that give rise tomuscle
tissue, cartilage and bone, and subcutaneous tissue of skins.
Signals for somite differentiation are derived from structures
surrounding mesoderm, such as notochord, neural tube, and
epidermis. Established markers of mesoderm are 𝛼-smooth
muscle actin (𝛼-SMA) and brachyury.
Muscle satellite cells (myosatellite cells) have been shown
as precursors of mature skeletal muscle cells [13]. The muscle
satellite cells have a potential to provide additional myonuclei
to their parental muscle fiber or return to a quiescent
state [14]. Tendon and ligament have been known to be
mesenchymal lineage as well.
2.5. Bone Marrow Stromal Cells and Mesenchymal Stem Cells.
Bone marrow stromal cells (BMSCs) have been shown to
contain mesenchymal stem cells (MSCs) that have abilities
to differentiate to multiple lineages such as osteoblasts,
chondrocytes, and adipocytes. Osteoblasts are lining on the
surface of and producing bone matrix, while osteocytes, the
further differentiated cells of osteoblasts, are embedded in the
lacuna in the calcifiedmatrix, extending communicative den-
drites into canaliculi for mechanotransduction [15]. Defined
Stem Cells International 3
transcription factors can induce differentiation of MSCs into
expertized lineages, for example, Sox9 in initial chondroge-
nesis [16], Runx2 in osteoblast precursor and chondrocyte
hypertrophy [17], Osterix/Sp7 in later osteogenesis [18, 19],
PPAR𝛾 in adipogenesis [20], and MyoD in myogenesis [21].
2.6. Endothelial Cells, Haematopoietic Stem Cells, and Blood
Cells. Haematopoietic stem cells (HSCs) and cardiovascular
systemhave been known to be differentiated frommesoderm.
Whether blood cells arise from mesodermal cells, mes-
enchymal progenitors, bipotent endothelial-haematopoietic
precursors, or haemogenic endothelial cells had remained
controversial, but haemangioblasts have been known to
differentiate to endothelial cells as well as to blood cells.
Lancrin et al. showed that the haemangioblast generates
haematopoietic cells through a haemogenic endothelium
stage [22]. Eilken et al. showed that using new imaging and
cell-tracking methods, embryonic endothelial cells could be
haemogenic [23]. Boisset et al. showed that using in vivo
imaging, the dynamic de novo emergence of phenotypically
defined HSCs, which were Sca1(+), c-kit(+), and CD41(+),
directly from ventral aortic haemogenic endothelial cells
[24]. Bertrand et al. (2010) showed that HSCs derive directly
from aortic endothelium during development [25]. Chen
et al. showed that Runx1 is required for the endothelial
to haematopoietic cell transition but not thereafter [26].
Kissa and Herbomel showed that blood stem cells emerge
from aortic endothelium by an endothelial-haematopoietic
transition [27].
Blood haematopoietic cells have been known to be
derived frommesoderm and located in the red bonemarrow.
HSCs are the stem cells that give rise to all the other blood
cells through the process of haematopoiesis [28]. The HSCs
give rise to the myeloid and lymphoid lineages of blood cells.
Myeloid cells includemonocytes, macrophages (M1 andM2),
neutrophils, basophils, eosinophils, erythrocytes, dendritic
cells (DCs), megakaryocytes, or its products platelets. Bone-
resolving multinucleated osteoclasts are one of the mature
cells derived from monocytes that differentiate to mononu-
cleic osteoclast precursor leading to osteoclastic cell fusion.
Lymphoid cells include T cells (T helper 1 cells, T helper 2
cells, and T helper 17 cells, also known as Th1, Th2, andTh17
cells, etc.), B cells, and natural killer (NK) cells. HSCs consti-
tute 1 : 10,000 of cells in the myeloid tissue in bone marrow.
Artery, vein, nerves, and lymphatic vessels are entering and
extending in bone. As part of the lymphatic system, lymph
vessels are complementary to the cardiovascular system.
2.7. Endoderm Including Definitive Endoderm and Mesoen-
doderm. Endoderm is an origin of multiple organs such
as pancreas (Pdx1, Ngn3, Ins are the markers), liver, gut,
intestine, lung, thyroid gland and thymus, urinary system
such as urinary bladder, and urethra. The endoderm consists
of flattened cells, which subsequently become columnar. It
forms the epithelial lining ofmultiple systems.The embryonic
endoderm develops into the interior lining of the digestive
tube and respiratory tube.
Endoderm gives rise to definitive endoderm (DE)
and visceral endoderm. Interestingly, a part of DE forms
mesendoderm that is originated from common precursor
cells derived from mesoderm and endoderm. The DE gives
rise to the gastrointestinal organs, such as stomach, pancreas,
liver, and intestine. Recent studies have identified several
germ layer-specific markers of the early DE. Sox17 is a DE-
specific marker [29]. CXCR4 (C-X-C chemokine receptor
type 4), which is expressed in the mesoderm as well as
in the DE and is used in combination with E-cadherin,
which is also expressed in ES cells and ectoderm, for the
prospective isolation of embryonic or ES cell-derivedDE cells
[30]. Dr. Kume’s group identified DAF1 (decay accelerating
factor)/CD55 and Cerberus1 (Cer1) as novel DE markers
[31, 32]. Shiraki et al. reported differentiation and character-
ization of ES cells into three germ layers using mesoderm-
derived feeder M15 cells [33, 34]. In this study, stimulation
with a combination of activin and bFGF induced ES cell
differentiation to mesendoderm, endoderm, and pancreatic
precursor cells; stimulation with Bmp7 induced differenti-
ation to mesoderm; the addition of p38 MAPK inhibitor
SB203580 induced differentiation to neuroectoderm. Further
long-term culture enabled neuroectodermal differentiation
to neuron, astrocytes, and oligodendrocytes andmesodermal
differentiation to osteoblasts and adipocytes. It was also
shown that stimulation of endoderm with a combination of
HGF and dexamethasone induced differentiation to hepato-
cytes.
Characterization of stem cells in the development of
bodies, organs, and tissues has been our scientific interests
while the multipotency of differentiation, proliferation, and
self-renewal have been emerging in clinical applications.
3. Induced Pluripotent Stem Cells
In 2006, Takahashi and Yamanaka reported induction of
pluripotent stem (iPS) cells from mouse adult fibroblast cul-
tures by defined factors [1]. Before this study, numerous tran-
scription factors (TFs) had been shown to be critical to induce
or maintain certain cellular differentiation stages including
ES cells. Dr. Yamanaka’s group aimed to know which factors
were required for induction of ES cells-like pluripotency.
More than 20 transcription factors and their combinations
were examined using retrovirus-mediated transduction in
skin fibroblasts. Nanog is one of the TFs that are expressed
in ES cells, and Nanog promoter-driven green fluorescence
protein (GFP) reporter was used as a marker for the screen-
ing of the TFs. Another marker is the colony formation
ability of pluripotent stem cells. Utilizing these significant
features, Dr. Yamanaka’s group finally discovered that ES
cells-like colonies were induced from skin fibroblasts using
combination of four defined factors, Klf4, Oct-3/4 (Pou5f1),
Sox2, and c-Myc. The ES cells had been known to have
an ability to form teratoma upon injection to experimental
animals. Both ES and iPS cells generated from skin fibroblasts
indeed formed teratoma upon subcutaneous injection to
mice. Finally, the ESC-like iPSCs were shown to be able to
give rise to embryos.These results were enough to say that the
cells were pluripotent.The iPS cells were next generated from
human dermal fibroblasts [35]. So far, established markers of
ES and iPS cells are SSEA-3, SSEA-4, TRA-1-60, TRA-1-81,
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Figure 1: Summary of published intermolecular interactions featuring pluripotency-associated miRNAs and their targets. Factors positive
to induction of pluripotency was shown in red. Inhibitory factors to induction of pluripotency was shown in blue. Epithelial-mesenchymal
transition (EMT), cell cycle, and cell death and survival were featured. Molecularly targeted drugs are shown with drug marks. T.S., tumor
suppressor.
Oct-4 (Pou5f1), Nanog, Sox2, Klf4, MycN, Lin28, Cripto,
Fbx15, Dnmt3b, Fgf4, Gdf3, Rex1, miR-200c, miR-302 family,
miR-369-3p, and miR-369-5p.
3.1. Improvement of Methods in Generation of iPS Cells. After
this breakthrough of iPS cells, researchers have made the
effort to reduce risks of oncogenesis, which could be induced
during the reprogramming. The risk included the usage of
viral vectors that could be integrated into genomic DNA
and the usage of an oncogene c-myc. Replacement of the
viral vectors to plasmid vectors enabled to generate iPS
cells while induction efficiency was reduced [36]. One clue
was that the oncogenic c-myc is a member of Myc family
that includes other two members N-myc and L-myc. Dr.
Yamanaka’s group replaced the c-myc to N-myc and L-myc
[37]. Indeed, iPS cells were generated using N-myc instead of
c-myc.
It had been known that p53–p21 pathway served as a
barrier in tumorigenicity (Figure 1). Dr. Yamanaka’s group
demonstrated that the p53–p21 pathway was also a barrier in
the generation of iPS cells [38].The discovery of iPS cells and
the recovery from the tumorigenic risk have made the cells
more feasible toward clinical applications.
3.2. Clinical Application of Pluripotent Stem Cells. The appli-
cation of ES and iPS cells has been thought for regenerative
medicine. The cells or tissues generated by the reprogram-
mingmight be useful for transplantation therapies. Hotta and
Yamanaka reviewed clinical applications of pluripotent stem
cells in their recent publication entitled “From Genomics to
GeneTherapy: Induced Pluripotent StemCellsMeet Genome
Editing” [39]. The world’s first phase I clinical trial using hES
cells was aimed to treat patients with spinal cord injuries.
In October 2010, oligodendrocyte progenitor cells derived
from H1 human ES cells were injected into the site of spinal
cord damage. Unfortunately, the trial was terminated in 2013
after the biotech company Geron decided to withdraw from
the stem cell business. The second clinical trial using hES
cells investigated Stargardt’s macular dystrophy (SMD) and
advanced dry age-related macular degeneration (Dry AMD)
by using retinal pigment epithelium (RPE) cells derived from
ahumanES cell lineMA09.Thefirst patients for each trial was
treated in 2011. As a phase I study to test feasibility and safety,
there were no signs of tumorigenicity of apparent rejection
[40]. The third example of an ES cell-related clinical trial is
for type I diabetes. Pancreatic precursor cells (called PEC-01
cells) from CyT203 human ES cells [41] were encapsulated
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into a device, Encaptra, and transplanted into a patient in
2014 as a phase I/II clinical trial. In all trials, transplantation
of human ES cells-derived products was allogenic and has
been conducted without matching HLA types. Therefore, the
current applications are mainly limited to immune privileged
tissues, such as eyes and spinal cord. iPS cells have been
investigated in an autologous transplantation setting. In
September 2014, the first transplantation of RPE cells derived
from iPS cells [42] for Wet AMD was conducted by Dr.
Takahashi’s group at RIKEN CDB in Japan.
A potential application of iPS cells has been advocated
that this concept and methods can be useful for generation
of disease model, in which cells can be reprogrammed from
patient cells. Such patient-derived iPS cells can be reasonably
used for drug screening. Yahata et al. (2011) reported anti-
amyloid 𝛽 (A𝛽) drug screening platform using human-iPS
cells-derived neurons for the treatment of Alzheimer’s disease
[43]. Dr. Takahashi’s group (2014) reported integration-free
iPS cells derived from retinitis pigmentosa patient for disease
modeling [44]. Suzuki et al. reported that pluripotent cell
models of Fanconi anemia identify the early pathological
defect in human haemoangiogenic progenitors [45].
Genetic linkage analysis and recent genome-wide associ-
ation studies (GWAS) meta-analysis have identified human
genetic variation/mutations associated with diverse dis-
eases and physical characteristics [46]. Genetic variations/
mutations with diseases could be corrected to normal or
lower risk variation with genome editing technologies using
CRISPR/Cas9 that requires noncoding guide RNA (gRNA)
[47]. Indeed, Kazuki et al. reported complete genetic correc-
tion of iPS cells from Duchenne muscular dystrophy (DMD)
[48]. Morishima et al. reported that genetic correction of
HAX1 in iPS cells from a patient with severe congenital
neutropenia improves defective granulopoiesis [49]. Further
application of iPS cells in combination with genome editing
therapy and for generation of disease model in terms of drug
discovery is ongoing.
4. MicroRNAs Involving Pluripotent
Stem Cells
MicroRNAs (miRNAs) are short noncoding RNAs that target
long RNAs leading to inhibition of translation and/or pro-
motion of mRNA degradation. miRNAs are generated from
miRNA cluster or intron of coding RNA. These resources of
miRNA are transcripts of genomic DNA. miRNA also have
been thought to be useful as biomarkers, tools for cellular
reprogramming, and therapeutic targets.OnemiRNA species
targets multiple long RNA leading to translational inhibition
of multiple proteins. Nevertheless, several challenges to
control cellular stemness and differentiation by miRNA have
been done.
4.1. MicroRNA-302/367 Cluster Targets Multiple Factors
Involving Epithelial-Mesenchymal and G1-S Transitions.
miRNA-induced pluripotent stem cells (mirPSC) were
firstly reported using human skin cancer cells. Lin et al.
reported that miR-302 reprogrammed human skin cancer
cells into a pluripotent ESC-like state [50]. This group firstly
reported that the miR-302 family members (miR-302s) were
expressed most abundantly in slowly growing human ES
cells and “quickly” decreased after cell differentiation and
proliferation. Therefore, they hypothesized that miR-302s
could be one of the key factors essential for maintenance
of ESC-renewal and pluripotency. The miR-302-transfected
cells expressed key ES cell markers such as Oct3/4, SSEA-3/4,
Sox2, and Nanog but also had a highly demethylated genome
similar to a reprogrammed zygotic genome. Microarray
analysis further revealed that genome-wide gene expression
patterns between the mirPSCs and human ES cells H1 and
H9 shared over 86% similarity. Using molecular guidance
in vitro, this mirPSC could differentiate into distinct tissue
cell types such as neurons, chondrocytes, fibroblasts and
spermatogonia-like cells. Based on these findings, this group
concluded that miR-302s function to reprogram cancer cells
into an ES-like pluripotent state but also to maintain the
stem cell state under a feeder-free cultural condition.
Thereafter, Barroso-del Jesus et al. (2009) released per-
spectives regarding the miR-302/367 cluster as a potential
stemness regulator in ES cells [51]. Later miRNA profiling
studies reproduced that miR-302 was essentially expressed
specifically in ES and iPS cells and lost upon differentiation
and proliferation. One such profiling was carried out by
Wilson et al., who reported microRNA profiling of human-
iPS cells termed microRNAomes [52]. This group confirmed
that the presence of a signature group of miRNAs that is
upregulated in both iPS and hES cells, such as the miR-
302/367 and miR-17/92 clusters. Another miRNA profiling
was carried out by Stadler et al., who reported the charac-
terization of microRNAs involved in a state of ES cells [53].
This group showed that defined hES cells-enriched miRNA
groups (miR-302, miR-17, miR-515 families, and the miR-
371-373 cluster) were downregulated “rapidly” in response to
differentiation.
One arising question was what factors were targeted
by miR-302. The first report of targets of miR-302 in ES
and iPS cells was regarding cell cycle regulators. Card et al.
showed that Oct4/Sox2-regulated miR-302 targeted mRNA
encoding cyclin D1 in hES cells [54] (Figure 1). Lin et
al. reported that maintaining slowly proliferating adhesive
stem cells will require inhibition of cell cycle by miR-
302/367 that targets cyclin D1 and cyclin-dependent kinases
2/4/6 (Cdk2, Cdk4 and Cdk6) [55]. Nevertheless, cell cycle
must be rotated for mitosis of iPS and ES cells. A tumor
suppressor p53 had been shown to upregulate p21⋅Cdkn1a
(Cdk inhibitor 1a). p21/Cdkn1 had been known to inhibit
Cdk2/cyclin E (CcnE) complex leading to G1/S arrest. Wang
et al. reported that ES cell-specific microRNAs regulated G1-
S transition and promote rapid proliferation [56]. In this
study, G1-S arrest factors including p21/Cdkn1a, p130/Rbl2,
and Lats2 were shown to be targeted by 5󸀠-UAAAGUGC. . .-
containing or AAAGUGCU. . .-containing microRNAs such
as miR-291, miR-294, miR-295, and miR-302d. This work
explained how the miR-302 overcame the G1-S arrest at
the G1-S transition. Lin et al. (2011) reported that miR-302
targeted cosuppression of four “epigenetic” regulators, lysine
demethylase KDM1 (also known as LSD1/AOF2), AOF1,
p66/MECP1, and MECP2 [57].
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Targeting TGF𝛽 signaling by miR-302 may reprogram
cells toward generation of iPS and mirPS cells through
induction of mesenchymal-epithelial transition (MET), the
acquisition of intercellular adhesion. Pluripotent stem cells
have characters to form colonies along with acquirement
of intercellular adhesion. Intercellular adhesion is known
largely to be lost during EMT in tissue development. The
most significant inducer of EMT is TGF𝛽, and loss of TGF𝛽
signaling can induce epithelial phenotypes with intercellular
adhesion. Thus, the generation of iPS cells may require MET
along with the acquisition of intercellular adhesion.
Sequencing of RNA transcripts revealed that a pre-
miRNA cluster encoded five miRNAs including miR-302a,
-302b, -302c, -302d (miR-302s), and miR-367, termed miR-
302/367 cluster. Liao et al. reported that the miR-302/367
cluster enhanced somatic cell reprogramming (SCR) by
accelerating anMET through targeting TGF𝛽 type II receptor
(TGFbR2) and increased E-cadherin expression [58]. BMP
signaling had been known as being required for maintenance
of ES cells. Lipchina et al. reported that miR-302/367 cluster
promotes BMP signaling by targeting BMP inhibitors TOB2,
DAZAP2, and SLAIN1 [59] (Figure 1). Li et al. reported that
not only miR-302 but also miR-93 targets mRNA encoding
TGFbR2 to enhance generation of iPS cells [60]. Anokye-
Danso et al. reported miRNA-302/367-mediated reprogram-
ming of mouse and human somatic cells to pluripotency
[61]. This work showed an extremely higher efficiency of ES
cell-like colony formation with ES cell-like morphology and
expression of markers using miR-302/367 cluster compared
to OSKM-iPS. In this study, the number of colonies with ES
cell-like morphology per 100,000 cells was 10396 cells using
miR-302/367 and only 3 with OSKM in this work. However,
one says that, for years, this work has not been reproduced
at all in any other groups or extensively used (given that
the efficiency in the paper is strikingly high). Poleganov
et al. reported that human fibroblasts and “blood-derived
endothelial progenitor” cells were efficiently reprogrammed
by transduction of nonmodifiedmiR-302/367 cluster in a sin-
gle vector leading to immune evasion [62].These works using
miR-302/367 showed that blocking mesenchymal TGF𝛽 sig-
naling and maintenance of BMP signaling were required
for generation and maintenance of iPS cells. Switching from
BMP to TGF𝛽 signaling may enable cells to differentiate to
mesenchymal lineage/phenotype.
Faherty et al. reported that CCN2/CTGF increased miR-
302s expression level [63] (Figure 1). CCN2 has been known
to associate with diverse extracellular proteins including
growth factors, cell surface molecules such as receptors and
integrin, and extracellular matrix proteins leading to modu-
lation of these partners [64, 65]. Thus, CCN2/CTGF may be
useful as a growth factor supporting cellular reprogramming
through induction of miR-302.
4.2. Combination of miR-200c Plus miR-302 s and miR-369
s Family. miR-200 family has been shown to repress EMT
through targeting Zeb1/Tcf8/deltaEF1, a master transcription
factor that represses E-cadherin gene (CDH1). Miyoshi et
al. reported “reprogramming of mouse and human cells to
pluripotency using mature microRNAs” [66, 67]. This group
used a combination ofmiR-200c plusmiR-302 s andmiR-369
s family of miRNAs without using OSKM factors. Miyoshi
et al. showed similarity and difference between mirPS and
ES cells in gene expression levels of markers such as Nanog,
Oct4, Cripto, Dppa5, Eras, Fbx15, and miRNAs, on which
they focused. Leonardo et al. featured these successfulmature
miRNA-driven reprogramming in a review entitled “the
functions of microRNAs in pluripotency and reprogram-
ming” [68].
4.3. miR-34a Induced by Tumor Suppressor p53 Targets Multi-
ple Pluripotency Factors, Cell Cycle Genes, and Antiapoptotic
Bcl2. The p53-p21 pathway had been known as a tumor
suppressor to G1-S arrest axis (Figure 1). Hong et al. showed
suppression of iPS cell generation by the p53–p21 path-
way [38]. In this study, iPS cell generation efficiency was
largely increased by knockdown and knockout of p53. In
other words, loss of the tumor suppressor p53 may induce
pluripotency in carcinogenesis. In the p53-null background,
iPS cells were generated from terminally differentiated T
lymphocytes.
Interestingly, in 2007, four groups reported that
microRNA-34 family members were a novel transcriptional
target of tumor suppressor p53 in human colon cancer
cells or in mouse embryonic fibroblasts (MEFs) [69–74].
In these works, it was shown that miR-34 family miRNAs
mediated cellular senescence (growth arrest) in human
colon cancer cells or MEFs and targeted a program of genes
promoting cell cycle progression such as E2F, Cdk4, CcnE2,
and Met (Figure 1). Referring to these works mentioned
above, Choi et al. showed that miR-34 provided a barrier
for somatic cell reprogramming [75]. This work showed
OSMK-triggered, p53-dependent induction of miR-34 s in
MEFs. This work also showed that miR-34a deficiency in
mice significantly increased reprogramming efficiency and
kinetics, while miR-34a and p21, the downstream factors of
p53, were cooperatively barrier of somatic reprogramming.
It was shown that suppression of reprogramming by
miR-34a was due to repression of pluripotency genes,
Nanog, Sox2, and N-myc. Cole et al. showed miR-34a
as a candidate tumor suppressor gene in neuroblastoma
through targeting antiapoptotic Bcl2 and pluripotency factor
N-myc [76] (Figure 1). Removing such barrier factors are
a reasonable strategy for the establishment of barrier-free
reprogramming in terms of efficient and reproducible
reprogramming.
5. Direct Reprogramming
The reprogramming of cells to iPS cells gives the cells
possessing abilities of pluripotency and self-renewal. Another
idea has been challenged that cells in a mature lineage could
be directly transdifferentiated into the other lineages using
defined factors termed as “direct reprogramming.” Since
EMT and MET have been shown during the development
of body and cancer, the induced transition from one lineage
to the other is realistic. Moreover, the short cut direct repro-
gramming without iPSC generationmay be more reasonable,
efficient, and beneficial for clinical application.
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5.1. Induced Chondrocyte-Like Cells (iChon). Dr. Nobuyuki
Tsumaki’s group have reported the direct reprogramming
of human dermal fibroblasts to chondrocytes using defined
factors [77–84]. A key idea was replacing Sox2 one of the
indispensable factors for the iPSC generation to its brother
Sox9 that is a master transcription factor for chondrogenesis.
This group has established a model of type II collagenopathy
skeletal dysplasia using direct conversion and iPS cells [85,
86].
5.2. Induced Neuronal Stem Cells (iNSC) and Induced Neurons
(iN). The combination of miR-124 and two TFs MYT1L and
BRN2 was sufficient for direct reprogramming of postnatal
and adult human primary dermal fibroblasts to functional
neurons [87]. Han et al. reported direct reprogramming of
fibroblasts into NSCs using defined factors including SMOK
factor plus TCF3/E47 [88]. The requirement of 𝛽-catenin
signaling for induced NSC (iNSC) was shown in this study,
because the TCF3 is a recipient TF of the Wnt/𝛽-catenin
signaling.
Not addition but subtraction of defined factors has
challenged for the iNSC generation. Ring et al. reported
direct reprogramming of mouse and human fibroblasts into
multipotent NSCs with only a single factor Sox2 in an “NSC
permissive culture condition” [89]. Wapinski et al. reported a
hierarchicalmechanism in the direct conversion of fibroblasts
into induced neurons (iN) cells mediated by Ascl1, Brn2, and
Myt1L transcription factors [90].
Guo et al. reported in vivo direct reprogramming of
reactive glial cells into functional neurons after brain injury
and in an Alzheimer’s disease model [91]. In the study,
retroviral expression of a single neural TF, NeuroD1 was used
for direct reprogramming of reactive glial cells into functional
neurons in vivo in the cortex of stab-injured or Alzheimer’s
disease model mice.
5.3. Induced Cardiomyocyte-Like Cells (iCM). Fu et al.
reported direct reprogramming of human fibroblasts toward
cardiomyocyte-like state [92]. This group first reported that
three TFs (GATA4,MEF2C, andTBX5) termedGMTdirectly
reprogrammed nonmyocyte mouse heart cells into induced
cardiomyocyte-like cells (iCMs). Then, this group showed
that GMT plus ESRRG and MESP1 induced global cardiac
gene expression and phenotypic shifts in human fibrob-
lasts. In addition, myocardin, ZFPM2, and TGF𝛽 signaling
were shown to be important for the iCM reprogramming.
Jayawardena et al. reported that a combination of miR-1,
-133, -208, and -499 was capable of inducing direct cellular
reprogramming of fibroblasts into cardiomyocyte-like cells in
vitro [93].
5.4. Induced Vascular Endothelial Cells (iVEC). Vascular
endothelial cells were generated from fibroblasts via partial-
iPSC reprogramming with four TFs required for iPSC gen-
eration and subsequent transduction of SETSIP with VEGF
[94]. This group showed the SETSIP translocated to nuclei
upon stimulation with VEGF and bound to the VE-cadherin
promoter and increased VE-cadherin expression levels and
EC differentiation.
5.5. Induced Osteoblast-Like Cells (iOB). Direct conversion
of human fibroblasts into functional osteoblasts by defined
factors was recently reported. Yamamoto et al. reported that
osteogenic transcription factors, Runx2, and Osterix/Sp7,
in combination with Oct4 and L-myc, drastically induced
fibroblasts to produce calcified bone matrix and osteoblas-
tic markers [95]. This group reported that the induced
osteoblasts (iOBs) into bone defects contributed to bone
repair in mice. In addition, iOBs did not require continuous
expression of the exogenous genes to maintain their pheno-
types. Mizoshiri et al. reported that L-myc in combination
with either Oct3/4, Oct6, or Oct9 enabled the conversion
of fibroblasts to osteoblasts [96]. Alternatively, Oct9 plus N-
myc had the strongest capability of inducing osteoblastic
phenotype. Prior to these iOBs studies, Song et al. reported
that loss of Wnt/𝛽-catenin signaling caused cell fate shift of
preosteoblasts to adipocytes [97].
MicroRNAs have been used for generation of iPSC and
direct reprogramming as described above. We have had an
idea that miRNA produced during osteogenic differentiation
from stem cells (termed OstemiR) may be biomarkers, tools,
and therapeutic targets, which are beneficial for patients
suffering fromosteoporosis, bone fracture, genetic osteogenic
disorders, arthritis, and aging. We screened such OstemiR
[98] (a partial list was shown in Table 1). The OstemiR
database provides gene expression signature of miRNA and
mRNA that were altered in osteoblastic/osteocytic differenti-
ation of MSCs. The combination of some OstemiR can be a
tool for direct reprogramming to osteogenic lineage.
6. miR-720 Promotes Dental Pulp (Stem)
Cell Differentiation via Targeting
Pluripotent Stem Cell Factor Nanog
We reported that microRNA-720 (miR-720) controlled stem
cell phenotype, proliferation, and differentiation of human
dental pulp cells [99]. Dental pulp includes mesenchymal
(stem) cells, peripheral nerves, blood vessels, and blood.
The mesenchymal stem cells have been known to have an
ability to differentiate to mature odontoblasts that produce
extracellular matrix proteins. We challenged a hypothe-
sis that dental pulp could include multipotent stem cells.
Side population (SP) cells, which had been known to be
enriched with stem cells having pluripotency, in dental pulp
cells were separated from main population (MP) cells with
fluorescence-activated cell sorting (FACS) usingHoechst blue
and Hoechst red. ABCG2, Nanog, and Oct-4 were expressed
at higher levels, while a level ofmiR-720 expression was lower
in SP cells compared to MP cells. miR-720 was predicted to
target Nanog, and this targeting was experimentally proven
(Figure 1). Neutralization of miR-720 using anti-miR-720 was
shown to repress odontoblastic differentiation.
7. miR-720 Promotes Dental Pulp (Stem)
Cell Differentiation through Induction of
DNA Methyltransferases
We showed that miR-720 positively regulated expression
of DNA methyltransferases Dnmt3a and Dnmt3b as well.
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In addition, overexpression of Dnmt3a and Dnmt3b pro-
moted odontoblastic differentiation of dental pulp cells and
repressed Nanog expression. Thus, it was suggested that
odontoblastic differentiation of dental pulp cells required
miR-720 that repressed Nanog and induces Dnmt3a and
Dnmt3b.
Prior to our study, roles for Dnmt3a/b in promotion of
HSC differentiation had been shown. Okano et al. showed
that Dnmt3a and Dnmt3b were essential for de novo methy-
lation and mammalian development, using Dnmt3a and
Dnmt3b deficient mice [100]. Mutations in human DNMT3B
were found in immunodeficiency, centromeric instability,
and facial anomalies syndrome (ICF syndrome) in this study.
Challen et al. (2012) showed that Dnmt3a was essential
for HSC differentiation [101]. In this study, loss of Dnmt3a
in HSCs led to higher expression of HSC multipotency
genes, Runx1, Gata3, and Nr4a2. Thus, it was suggested that
HSCs could differentiate into B cells via Dnmt3b-dependent
hypermethylation of Runx1, Gata3, Nr4a2, and Vasn genes.
Challen et al. (2014) reported that Dnmt3a and Dnmt3b
might promote DNA methylation in Ctnnb1, which encodes
𝛽-catenin, stem cell self-renewal factor, CcnD1 a G1-phase
cyclin gene, PparG an adipogenic transcription factor, and
VegfA and Jag1 genes [102]. The roles for Dnmt in HSC
differentiation may be similar with that in DPSCs. Thus,
targeting 𝛽-catenin, PAPR𝛾, and CcnD1 by Dnmt3a/3b is
thought to promote differentiation of cells in odontoblastic
and osteoblastic lineage.
These works suggested that direct reprogramming to
mature odontoblasts as well as osteoblasts could be chal-
lenged using a combination of miR-720 and Dnmt3a/3b
overexpression. Another idea is that dental pulp (stem) cells
are a good resource of cells having potential for generation
of iPS cells from dental pulp (stem) cells. Oda et al. reported
highly efficient generation of iPS cells from human third
molar mesenchymal stromal cells [103].
8. Conclusion
Improvement of concept, materials, and methods in cellular
reprogramming has given huge progress in life science and
medicine. Firstly, growth factors and transcription factors
were defined useful for generation of iPS cells. Later studies
have shown microRNAs are also useful for the generation
of iPS cells. Defined factors including growth factors, TFs,
and miRNAs have been shown to be useful for cellular repro-
gramming. The combination of the cellular reprogramming
with genome editing is ongoing in life science and medicine
toward benefits for patients in human society.
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